ISRCTN23062732已完成不适用
A randomized phase II trial comparing epirubicin, cisplatin, and capecitabine versus the combination of epirubicin, cisplatin, and capecitabine with pravastatin in patients with irresectable or metastatic gastric carcinoma
Erasmus Medical Center, Department of Medical Oncology (Netherlands)0 个研究点目标入组 43 人开始时间: 2006年1月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histologically proven, irresectable gastric adenocarcinoma, except carcinoma of the cardia
- •2. WHO 0-2
- •3. Ability to swallow
- •4. Adequate hepatic, renal and bone marrow function
排除标准
- •1. Prior chemotherapy or radiotherapy
- •2. Current treatment with HMG-CoA-reductase inhibitor
- •3. Peripheral neurotoxicity grade >2
研究者
相似试验
招募中
不适用
Phase II randomized controlled trial of epirubicin hydrochloride and miriplatin hydrate as anticancer agents for transcatheter arterial chemoembolization of hepatocellular carcinomahepatocellular carcinomaJPRN-UMIN000011785Takasaki General Medical Center, National Hospital Organization60
招募中
不适用
A randomized phase II trial comparing epirubicin, cisplatin, and capecitabine versus the combination of epirubicin, cisplatin, and capecitabine with pravastatin in patients with irresectable or metastatic gastric carcinoma.advanced irresectable or metastatic gastric carcinomaNL-OMON27982ot applicable43
进行中（未招募）
1 期
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine and Herceptin in Early Breast Cancerearly HER-2 breast cancerEUCTR2004-002030-19-ATAUSTRIAN BREAST CANCER STUDY GROUP536
已完成
不适用
A phase II/III randomised trial comparing Epirubicin, Cisplatin and Protracted Venous Infusion (PVI) 5-Fluorouracil (5-FU) (ECF), Epirubicin, Oxaliplatin and PVI 5-FU (EOF), Epirubicin, Cisplatin and Capecitabine (ECX) and Epirubicin, Oxaliplatin and Capecitabine (EOX) in Patients with Advanced Oesophago-Gastric CancerCancerISRCTN51678883The Royal Marsden NHS Foundation Trust (UK)1,000
进行中（未招募）
1 期
A Randomised Phase II trial of Epirubicin, Oxaliplatin and Capecitebine (EOX) versus Docetaxel and Oxaliplatin (EITax) in the treatment of Advanced Gastro-oesophageal cancer - The ELECT trial - ELECT trialAdvanced Gastro-oesophageal cancerMedDRA version: 9.1Level: LLTClassification code 10062878Term: Gastrooesophageal cancerEUCTR2006-003332-29-GBICORG, all-Ireland Cooperative Oncology Research Group140